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Key points
●● Primary ciliary dyskinesia (PCD) is a genetically and clinically heterogeneous disease characterised 
by abnormal motile ciliary function.
●● There is no “gold standard” diagnostic test for PCD.
●● The European Respiratory Society (ERS) Task Force Guidelines for diagnosing PCD recommend 
that patients should be referred for diagnostic testing if they have several of the following features: 
persistent wet cough; situs anomalies; congenital cardiac defects; persistent rhinitis; chronic 
middle ear disease with or without hearing loss; or a history, in term infants, of neonatal upper and 
lower respiratory symptoms or neonatal intensive care admission.
●● The ERS Task Force recommends that patients should be investigated in a specialist PCD centre 
with access to a range of complementary tests: nasal nitric oxide, high-speed video microscopy 
analysis and transmission electron microscopy. Additional tests including immunofluorescence 
labelling of ciliary proteins and genetic testing may also help determine the diagnosis.
Educational aims
This article is intended for primary and secondary care physicians interested in primary ciliary dyskinesia 
(PCD), i.e. those who identify patients for testing, and those involved in diagnosing and managing PCD 
patients. It aims:
●● to inform readers about the new European Respiratory Society Task Force Guidelines for diagnosing 
patients with PCD
●● to enable primary and secondary care physicians to: identify patients who need diagnostic testing; 
understand the diagnostic tests that their patients will undergo, the results of the tests and their 
limitations; and ensure that appropriate care is subsequently delivered.
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What is primary ciliary 
dyskinesia?
Primary ciliary dyskinesia (PCD) is a genetically and 
clinically heterogeneous disease characterised by 
abnormal motile ciliary function. It is inherited 
predominantly in an autosomal recessive pattern. 
Mutations in genes that encode ciliary proteins 
or assemble those proteins lead to abnormal 
function and ultrastructure of epithelial cilia in 
the lungs, paranasal sinuses, reproductive system 
and Eustachian tubes. Mucociliary clearance 
provides an important defence mechanism in the 
airways against bacteria and particulate debris. 
Patients with PCD therefore develop recurrent 
and chronic infections of upper and lower airways, 
and conductive hearing impairment [1]. Airway 
symptoms often start within a few hours of birth 
[2]. Many, but not all, males are infertile due to 
immotile sperm. Subfertility is probably an issue 
for some women, caused by immotile cilia in the 
Fallopian tubes, but data are lacking. Dysfunction 
of motile cilia in the embryonic node causes situs 
abnormalities in half of patients, e.g. situs inversus 
or situs ambiguous, which can be associated with 
congenital heart disease [3]. Very rarely, PCD is 
associated with hydrocephalus because of defective 
ependymal motile cilia, which propel cerebrospinal 
fluid through the cerebral ventricles; and with 
retinitis pigmentosa, inner ear deafness or renal 
disease because of defective nonmotile primary 
cilia, which act as photoreceptors in the eyes, 
stereocilia in the inner ear and mechanoreceptors 
in renal tubules [4].
Mutations in >35 genes are known to cause PCD 
but more are yet to be discovered [5]. The large 
number of PCD genes and even greater number 
of disease-causing mutations results in a disease 
that is highly heterogeneous in ciliary morphology 
and function. For example, DNAH5 is a gene that 
encodes a protein in the outer dynein arm (figure 1), 
a structure that drives the power needed for cilia to 
move [6]. Patients with biallelic mutations in DNAH5 
have cilia that are mostly static and transmission 
electron microscopy (TEM) will reveal missing outer 
dynein arm structures (figure 2a). CCDC39 and 
CCDC40 encode proteins that are essential for the 
assembly of dynein regulatory and inner dynein arm 
complexes. Patients with mutations in these genes 
have cilia that can move but have an extremely stiff 
ciliary beat with poor amplitude; analysis by TEM 
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shows microtubular disorganisation and missing 
inner dynein arms (figure 2b) [7].
PCD is underdiagnosed
PCD is estimated to affect one in 10 000 people, 
although the true prevalence is unknown and many 
patients remain undiagnosed. In populations with a 
high proportion of consanguineous marriages, such 
as British Asians, prevalence can be much higher: 
up to one in 2000 people, which is comparable to 
cystic fibrosis (CF) [8]. A European survey conducted 
in 2007–2009 found that in most countries, only a 
small fraction of PCD patients had been diagnosed, 
particularly among adults, with a wide variability 
between countries [9]. The reasons for under 
diagnosis are multifactorial. General practitioners, 
paediatricians and even pulmonary physicians rarely 
see a case, and their awareness of the condition 
is thereby limited. An international survey of PCD 
patients reported that 37% of patients had >40 
visits to medical professionals due to PCD-related 
symptoms before being referred for testing [10]. PCD 
symptoms are nonspecific and it is not surprising 
that patients with situs inversus, a rare condition in 
the general population, are diagnosed at an earlier 
age [9]. The need for highly specialised diagnostic 
tests, often available only at a long distance from the 
patients’ homes, contributes to underdiagnosis, as 
the availability of tests varies across Europe [11]. The 
situation is worse for adults and a disproportionately 
large percentage of patients in the International PCD 
Cohort are aged <20 years [12], whilst it is expected 
that most patients will live to later adulthood.
Assuming a prevalence of one in 10 000 and a 
near normal lifespan, we expect ∼800 PCD patients 
in Switzerland (population 8 million) and 6500 in 
the UK (population 65 million). Currently, we know 
of ∼120 diagnosed patients in Switzerland, of whom 
most are younger than 20 years, and about 600 in 
the UK, including ∼330 children aged <18 years. 
These figures illustrate the large proportion of 
undiagnosed patients, particularly among the adult 
population. If all patients with PCD were diagnosed, 
respiratory centres should have one PCD patient for 
every four to five CF patients cared for.
The PCD diagnostic Task 
Force of the European 
Respiratory Society
With the aforementioned concerns in mind, in 
2014, the European Respiratory Society (ERS) 
commissioned a Task Force to provide guidelines 
for the diagnosis of PCD. The group included adult 
and paediatric physicians from pulmonology and 
ear, nose and throat (ENT) disciplines along with 
diagnostic scientists. The Task Force developed the 
first evidence-based guidelines for the diagnosis of 
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Figure 1 Diagram of the ultrastructure of the normal ciliary axoneme in transverse section. Reproduced from [5].
a) b)
Figure 2 Electron microscopy images of defects seen in patients with primary ciliary dyskinesia. 
a) Outer dynein arm defect. b) Inner dynein arm and microtubular disarrangement. Reproduced 
and modified from [5].
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PCD, full details of which were recently reported 
[5]. The aim of this article is to provide a short and 
comprehensible summary of the guideline for use 
by primary and secondary care physicians.
What evidence did the Task Force 
use for the guidelines?
The Task Force agreed that a key question was 
“Which patients should be referred for diagnostic 
testing?” and for this, they evaluated clinical 
symptoms and nasal nitric oxide (nNO) as possible 
screening tests [5]. They then investigated the 
role of five diagnostic tests for making a definite 
diagnosis of PCD:
●● nNO
●● high-speed video-microscopy analysis (HSVA)
●● TEM
●● genotyping
●● immunofluorescence (IF) labelling of ciliary 
proteins
Throughout the process, they used the rigorous 
Grading of Recommendations Assessment, 
Development and Evaluation approach for 
formulating questions for the systematic reviews, 
from grading the evidence to deciding the strength 
of recommendations [13, 14].
To determine the value of diagnostic tests, the 
Task Force required studies that mimic the clinical 
situation. Thus, they should include patients 
referred for PCD testing in whom the diagnosis is 
initially uncertain. Therefore, case–control studies 
that compare previously diagnosed typical PCD 
patients with healthy controls or patients with other 
diagnosed diseases such as CF are of little use since 
this situation does not occur in clinical practice. 
Only a minority of published studies had a suitable 
study design for the Task Force. For instance, the 
systematic search identified 98 manuscripts about 
nNO but only four met the inclusion criteria for 
study design; none of the studies on genetics or 
immunofluorescence met the criteria [5].
Which patients should be 
referred for PCD diagnostics?
How many PCD patients are 
expected in a typical practice?
A typical primary care physician (general practitioner 
(GP) or general paediatrician) in Europe cares for 
∼2000 persons. This means that they are expected 
to have 0.2 patients with PCD at any time. This 
corresponds to one patient per five primary care 
physicians or one patient in the lifetime of a GP 
who works several decades.
A specialist, such as a pulmonologist or ENT 
physician, might cover a region with 20 000 
inhabitants and, on average, would be expected 
to have two PCD patients in their practice and to 
make a new diagnosis every 40–50 years. Thus, not 
just primary care physicians but even pulmonary or 
ENT specialists have limited expertise with PCD. In 
order to improve diagnosis of PCD (and other rare 
diseases), primary care physicians, specialists and 
PCD centres need to coordinate their roles (figure 3).
Primary care physicians
GPs and general paediatricians should triage. 
Amongst the many patients with respiratory 
symptoms, they need to identify the patients who 
need to be referred to a specialist (pulmonologist or 
ENT physician) because of severe or atypical disease.
Specialists
Paediatric or adult pulmonologists or ENT physicians 
should:
●● decide who amongst their patients with severe 
or atypical disease is likely to have PCD
●● rule out more common diseases that lead to 
chronic upper and lower respiratory morbidity, 
such as CF and immune deficiency
●● then refer the patients to a PCD diagnostic centre 
for further evaluations
PCD diagnostic centres
Diagnostic centres must have the technical facilities 
and expertise to make a state-of-the-art diagnoses 
and determine if the patient has “definite PCD”, if 
PCD is “highly likely” or “highly unlikely”, or whether 
test results remain inconclusive (see the section 
“Has the patient got PCD?”).
How can we identify patients who 
need PCD testing?
Is there a good screening test for PCD?
The Task Force concluded that we lack a satisfactory 
test for widespread screening for PCD [5, 15]. The 
best available approach is a combination of typical 
symptoms and nNO.
Can we use nNO to screen for PCD?
nNO on its own cannot be used to screen for PCD 
in primary or secondary care [15]. Although nNO 
is low in most patients with PCD, discrimination is 
not perfect. Some patients with PCD have normal 
nNO, while people with CF or even healthy people 
can have low values. Although the sensitivity and 
specificity are very good, the positive predictive 
value (PPV) of a low nNO reading depends on the 
prevalence of PCD in the studied population. In a 
PCD diagnostic centre where patients have been 
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referred based on typical clinical symptoms, ∼10% 
of patients will have PCD. In this setting, the PPV 
is 44%, meaning that 44% of patients with a low 
nNO have PCD [15]. However, in a primary care 
setting where one in 10 000 patients has PCD, 
the PPV is 0.06%. This means that nNO is of no 
use in the general population because only about 
one in every 2000 patients with a low nNO has 
PCD. If all patients with a low nNO measured 
in primary or secondary care were referred to a 
PCD reference centre, these centres would be 
hopelessly overloaded. Therefore, only patients 
with typical symptoms should be screened with 
nNO [15, 16]. In addition, it is technically not 
so easy to obtain valid test results for nNO, 
particularly for infants and children, and the 
physician needs experience with the method to 
get reliable results.
Can we determine whether patients are at high 
risk of PCD based on their clinical presentation?
Most information comes from a study that 
investigated diagnostic outcomes of 868 
consecutive paediatric and adult referrals to the 
Southampton PCD reference centre. Of these, 
641 had conclusive results after testing [17]. 
Symptoms at referral that had a high sensitivity 
for PCD were chronic wet cough (sensitivity 
93%), chronic rhinitis (81%), neonatal chest 
symptoms (75%) and neonatal unit admission 
(61%). Specificity was highest for congenital 
heart disease (98%), situs anomalies (94%), 
bronchiectasis (96%), neonatal rhinitis (94%), 
neonatal respiratory support (93%) and chronic 
ear perforation (91%). Prediction of a PCD 
diagnosis was improved when symptoms were 
combined in the seven-point questionnaire-based 
tool PICADAR (Primary Ciliary Dyskinesia Rule) 
[17]. PICADAR includes information on:
●● preterm birth
●● neonatal chest symptoms
●● admission to a neonatal intensive care unit
●● situs anomalies
●● congenital heart defect
●● persistent perennial rhinitis
●● chronic ear or hearing problems
The diagnostic value of combined symptoms was 
also highlighted in an independent study from 
the USA, which was not included in the guideline 
because it used a different study design [18]. It 
described 534 patients with high suspicion of 
PCD and used expert-predetermined questions to 
define and refine clinical features [18]. The study 
found that the combination of unexplained neonatal 
respiratory distress, early-onset year-round wet 
cough, early-onset year-round nasal congestion 
and laterality defects was most useful to distinguish 
PCD patients from others. However, both the UK 
and US studies were conducted at tertiary care 
PCD diagnostic centres, and thus do not reflect the 
spectrum and severity of patients seen by a normal 
pulmonologist in a practice or smaller hospital. The 
PPVs of theses scores, when used in primary or 
tertiary care, are in the same range as those for 
nNO alone [16].
Level of care
Primary, secondary, 
tertiary
Diagnosis
Treatment
Specialist/secondary 
care:
Paediatric or adult 
pulmonologist or ENT 
physician, working in
practice or small hospital
· Recognise patients with  
  severe or atypical lung 
  or ENT disease
· Refer to specialist
· Recognise among 
  severe or atypical 
  patients those 
  at high risk of PCD
· Refer to PCD diagostic 
  centre
· Perform combination of 
  highly specialised
  diagnostic tests
· Interpret results and 
  propose a diagnosis
Shared care
· Immunisations
· Exacerbations
· Other diseases and
  accidents
· Psychosocial support,
  other
Shared care
· Regular scheduled 
  follow-ups 
· Exacerbations etc.
Shared care
· Propose multidisciplinary 
  management plan
· Conduct annual review
Primary care physician
GP or general paediatrician
PCD diagnostic centre
One or very few national 
reference centres; 
international network
Figure 3 The role of primary care physicians, specialists and PCD diagnostic centres in diagnosing and managing patients with PCD.
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How can we improve referrals of patients?
Currently, the ERS Task Force guidance is that 
primary care physicians should refer patients with 
severe or atypical symptoms for further evaluation 
to specialists (paediatric or adult pulmonary and 
ENT physicians). These specialists should base their 
decision for referral of patients to a PCD diagnostic 
centre on a set of typical symptoms (table 1), 
possibly in combination with nNO. Common sense 
suggests we should modify the symptoms based 
on the age of patients but solid evidence from age-
stratified studies is still lacking [1].
Which tests are used in a 
PCD reference centre for 
diagnosis?
There is no single “gold standard” diagnostic 
test for PCD and diagnosis requires a number of 
technically demanding, sophisticated investigations 
[19, 20]. Therefore, the Task Force recommends 
conducting testing only in specialised centres with 
a high throughput of referrals [5]; they consider 
this necessary to provide experience of the range 
of normality and abnormality associated with PCD 
in comparison to respiratory patients without PCD 
(figure 3). The Task Force investigated the evidence 
for the five PCD tests in common use: nNO, HSVA of 
ciliary beat frequency and pattern, TEM, genotyping 
and IF staining of ciliary proteins (table 2). The 
availability and combination of these tests varies 
between countries, and the guidelines therefore 
provide some flexibility in which tests should be 
used; ideally, specialist centres will provide access 
to all tests that contribute to the diagnostic decision 
(figure 4).
Nasal nitric oxide
nNO was traditionally advocated only as a screening 
test for PCD [22]. The Task Force recommended that 
in addition to screening, nNO should be part of the 
battery of confirmatory diagnostic tests given its 
excellent sensitivity (90–100%) and good specificity 
(75–97%) [5]. Moreover, it is relatively easy to 
perform, noninvasive and affordable. Measurements 
in school-age children and adults should ideally 
use a chemiluminescence analyser with a velum 
closure technique [21]. There is some evidence that 
younger children who cannot make the breath-hold 
manoeuvre can have nNO measured during tidal 
breathing but the discrimination between PCD and 
non-PCD may be poorer, particularly in infants, in 
whom nNO is low even in healthy children [23]. 
In a study of 117 consecutive referrals for all 
ages, Marthin and Nielsen [24], reported high 
false-positive rates (36%) for pre-school children. 
Cheaper portable analysers might be used to screen 
for PCD in referring hospitals but measurements 
should be repeated in a specialist centre using the 
reference standard, a chemiluminescence analyser.
High-speed video-microscopy 
analysis
HSVA is an important part of the diagnostic 
portfolio but in isolation is not sufficient to rule 
PCD in or out; if both nNO and HSVA are normal, 
further investigation is not required in the 
majority of cases [5]. Patients with PCD have an 
abnormal ciliary function, and ex vivo assessment 
of ciliary beat frequency and ciliary beat pattern in 
Table 1 Characteristic symptoms in patients with PCD, stratified by age#
Neonates Situs abnormalities
 Normal situs (∼47%)
 Situs inversus totalis (∼47%)
 Situs ambiguus with or without cardiac defects (∼6–12%)
Neonatal respiratory distress
 At term with no risk factors
 Prolonged oxygen requirement
 Atelectasis on radiography
Persistent rhinorrhoea
Family history of PCD
Childhood Wet cough
 Typically starts in infancy
 Persistent, year-round, doesn’t completely resolve with 
antibiotics
Bronchiectasis
 Sometimes present in pre-school year
Chronic rhinitis typically starts in infancy
 Persistent, year round even when “well”
Otitis media with effusion (“glue ear”)
Conductive hearing loss
 Variability within and between patients, normal to 
requiring hearing aids
 Mucopurulent discharge complicates ventilation tube 
insertion (evidence poor)
Adolescents 
and adults
As for children, plus
 Bronchiectasis
  Almost universal by adulthood
 Rhinosinusitis, variability within and between patients; 
symptoms might include
  Persistent nasal blockage and discharge
  Conductive hearing loss
  Sinusitis
  Anosmia
  Nasal polyposis
 Male infertility (not 100% and incidence unclear)
 Female fertility issues (incidence unclear)
Not all symptoms may be present. Although individual symptoms are 
nonspecific, the combination of symptoms is a strong indicator. The early onset 
and persistence of airway symptoms is typical. #: as hardly any of the available 
publications has been stratified by age, this table is mainly based on the authors’ 
expert opinion and will change as good epidemiological data become available; 
it is based mainly on the pulmonologist’s perspective, as few papers come 
from ENT, fertility, cardiology or neonatal services and reflect their patient mix.
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respiratory epithelium from the nose or bronchus is 
informative. For patients, nasal sampling is a quick 
but uncomfortable procedure. Many patients with 
PCD have clearly visible abnormalities of ciliary 
function (e.g. static cilia or rotating cilia) but some 
have more subtle defects such as an incomplete 
sweep. Analyses should therefore only be conducted 
by experienced observers, and always combining 
ciliary beat pattern and frequency. Although the 
results of HSVA are available on the day of testing, 
further analyses are often needed because 
secondary defects (caused by sampling, bacteria 
or viruses) cannot be distinguished from subtle 
abnormalities of function seen in some variants 
of PCD. Reanalysis by HSVA following culture of 
the cells can improve the diagnostic accuracy by 
mitigating secondary defects [25, 26]. Again, this 
needs specialised laboratories with experience in 
culture of ciliated cells.
For patients with abnormal nNO or HSVA, further 
tests are needed to confirm the diagnosis.
Transmission electron microscopy
TEM is an expensive and time-consuming 
investigation, again requiring the expertise of 
a specialist centre to identify abnormalities of 
ciliary ultrastructure (e.g. absent dynein arms and 
microtubular disarrangement) (figure 2). The ERS 
Task Force recommended that since TEM is highly 
specific (>99%) and can confirm a diagnosis, it 
provides a key part of the diagnostic process [5]. 
However, TEM is normal in 15–20% of patients with 
PCD and it therefore cannot be used in isolation to 
exclude a diagnosis [5].
Genotyping
The role of genetic testing as a diagnostic tool for 
PCD could not be evaluated by the Task Force in 
an evidence-based way, as there were no studies 
designed to assess this question. Currently, 
causative genes can be identified in ∼65% of 
PCD cases and we anticipate that this will improve 
as new genes are discovered [5]. Although the 
poor sensitivity means that genotyping cannot 
be used in isolation, the Task Force agreed that it 
can be used to confirm a diagnosis in patients with 
other abnormal tests (e.g. HSVA) or where there 
is a high index of suspicion (e.g. a good clinical 
history but normal TEM, as can be the case for 
patients with DNAH11 or RSPH mutations) [5]. 
Genetic testing and interpretation of results is 
not straightforward and needs experts who are 
aware of the complexities of PCD genotyping, and 
follow national and international best practice 
guidelines.
Immunofluorescence
Similarly, the Task Force found no studies on the 
use of IF as a diagnostic test for PCD. However, 
shortly after publication of the guidelines, a single-
centre study reported on 368 patients referred for 
PCD diagnostic testing and a further 35 patients 
with an established diagnosis [27]. Using six ciliary 
Before testing
Clinical history
nNO low and
HSVA “hallmark” abnormal 
  on 3 separate occasions
History very strong,
or test results 
abnormal/equivocal
History not strong
and tests normal
Step 1
nNO and HSVMA
(both repeated 3 times)
PCD
highly unlikely
PCD
highly likely
Consider Step 3 
if available
Further tests unlikely
to be needed
Step 2
TEM and cell culture
± repeat HSVA
Step 3
Genetic testing
Consider Step 3 
if available
PCD positive
“Hallmark” TEM defect
nNO  low and 
HSVA aer cell culture suggests 
  PCD 
Normal TEM
Consider additional investigations,
  e.g. radioaerosol mucociliary 
  clearance; recall patient for further   
  testing in the future when new 
  tests become available
Pathogenic biallelic mutations
Tests normal or equivocal,
or history very strong
History very strong and 
test results normal/equivocal
History not very strong and 
TEM normal and 
nNO normal and 
HSVA normal aer cell culture
Figure 4 Algorithm for diagnostic assessment of patients for PCD proposed by the ERS Task Force. This is a simplified version of the previously published 
diagram; see the full Task Force report [5] for details.
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antibodies, they found IF to be highly specific for 
PCD and to be considerably quicker than TEM. 
However, they showed that, as for TEM and genetic 
testing, the sensitivity of IF is currently limited and 
concluded that IF is not suitable as a standalone 
test [27].
What should happen after 
diagnostic tests?
When a patient referred to a reference centre for 
possible PCD returns with the test results to the 
referring physician, several questions arise.
Has the patient got PCD?
With the currently available diagnostic tests, the 
decision of whether a patient has or has not got 
PCD is not always straightforward. There is no 
test or combination of tests that can exclude PCD 
with 100% certainty. The Task Force therefore 
recommends a standardised terminology to describe 
the results of the testing (figure 4). If the patient 
has a hallmark TEM defect or biallelic causative 
mutation in PCD genes, they are diagnosed as “PCD 
positive”. If all currently available tests have been 
completed but neither of the two criteria is fulfilled, 
the patient is labelled as “PCD highly likely” if nNO 
is repeatedly low and hallmark HSVM alterations 
are found on three separate occasions or after cell 
culture, or as “PCD highly unlikely” if all tests were 
normal.
Even in experienced PCD diagnostic centres, a 
few patients will have inconclusive results because 
not all tests are available in the diagnostic centre 
or because they could not all be performed (for 
instance, in infants or when consent is refused). 
The following recommendations on continuing 
care (figure 5) are based on these diagnostic 
groups.
How should the patient be 
managed following diagnostic 
testing?
As for all rare severe diseases, patients should be 
managed in a shared care setting (figure 5). The way 
tasks are shared between healthcare providers will 
differ by country. We propose a possible setting but 
emphasise that these are their personal suggestions 
and not derived from the Task Force, which did not 
ResearchTreatmentNext stepsDiagnostics
To be discussed with 
multidisciplinary team
To be discussed with 
multidisciplinary team
Counsel family on 
outcome of tests
Facilitate contact with 
patient support groups
Genetic counselling
Assess comorbidities 
and complications of 
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Perform
  Echocardiography
  Abdominal ultrasound
  ENT consultancy
  Fertility consult (adults)
Set up multidisciplinary 
treatment plan led by PCD 
expert
Set up shared care
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  Regular airway clearance 
    (physiotherapy)
  Physical exercise
  Treatment of conductive 
    hearing loss
  Regular surveillance for 
    airway infections
  Antibiotics for acute 
    infections
Include patients in 
national or 
international PCD 
registries and 
cohort studies to 
make data available 
for research
Participate in 
collaborative 
observational and 
interventional 
studies on 
diagnostics and 
treatment
Participate in 
PCD clinical and 
research 
networks, such the 
COST Action BEAT-
PCD
Consider
  Lung MRI or CT 
  Other specialist   
    consultancies   
    (opthalmologist, etc.)
Consider
  Preventative antibiotics
  Treatment of comorbidities   
    if needed (cardiac defects, 
    infertility, hyposplenism, etc.)
Counsel that PCD is 
unlikely and further 
PCD tests not needed
Exclude alternative 
diagnoses leading to 
similar symptoms
Repeat PCD testing 
periodically as 
improved tests become 
available
Counsel that PCD is 
highly likely but cannot 
be proven due to 
limitations of available 
tests
Counsel that the 
diagnosis PCD is certain
PCD
highly unlikely
Results
inconclusive
PCD
highly likely
PCD
positive
Figure 5 Further steps after diagnostic workup and management for patients with positive, highly likely, highly unlikely and inconclusive diagnostic data. MRI: 
magnetic resonance imaging; CT: computed tomography.
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comment on management (only on diagnostics). 
We suggest (figure 5):
●● The PCD reference centre proposes a 
multidisciplinary management plan adapted 
to the patient and sees the patient at defined 
intervals (e.g. yearly) for a standardised 
assessment of the clinical course and for 
proposing additional tests or therapies based 
on upcoming evidence.
●● The specialist (pulmonary or ENT physician) sees 
the patient in between these annual reviews (e.g. 
every 3 months), adapts therapies to the clinical 
course and treats exacerbations.
●● The primary care physician performs all 
recommended immunisations, treats 
exacerbations and other (independent) diseases, 
and organises local therapeutic and psychosocial 
support if needed.
Depending on the healthcare system in the country 
and region (rural or urban), tasks could be swapped 
from the specialist to the PCD centre, from the 
specialist to the GP or from the GP to the specialist. 
However, we feel strongly that the management 
plan should be set up and regularly monitored by 
a tertiary care reference centre that is specialised 
for PCD.
Positive
For patients with a positive diagnosis of PCD, best 
practice includes counselling of the family regarding 
the outcome of the diagnostic tests, describing and 
starting the management of this lifelong condition, 
genetic counselling, and further assessments to 
investigate comorbidities and complications of PCD 
(figure 5). This includes investigations, in all patients, 
for clinically important defects associated with 
situs ambiguus (ECG and abdominal ultrasound), a 
thorough ENT investigation and fertility counselling 
for adults. Additional investigations (lung magnetic 
resonance imaging or computed tomography, 
ophthalmologic examination, etc.) are organised 
on a case-by-case basis. These investigations 
are best performed in the PCD centre or in close 
collaboration with it. Counselling of patients and 
their families by multidisciplinary professionals with 
expertise in PCD is important at this early stage, and 
additional information and support can be provided 
by patient organisations (e.g. http://pcdsupport.
org.uk, www.kartagener-syndrom.org and www.
pcdfoundation.org).
Evidence for treatment is poor but the consensus 
of experts in the field suggests that multidisciplinary 
management should include regular airway 
clearance (physiotherapy) and exercise, a low 
threshold for antibiotic treatment of respiratory 
exacerbations, assessment and management of 
conductive hearing loss, and regular surveillance 
for airway infections [28]. Additional management 
is decided on a case-by-case basis. For example, 
some patients require treatment for cardiac defects, 
hyposplenism or infertility.
Highly likely
Where PCD is highly likely (figure 5), repeat testing 
or further investigations such as radioaerosol 
mucociliary clearance studies [29, 30] might be 
recommended by the PCD centre. However, a 
significant minority of patients will remain without 
a clear outcome. The Task Force recommends that 
if the diagnosis is highly likely, the patient should 
be told that they probably have PCD but given 
the limitations of current diagnostic tests, the 
diagnosis is not 100% certain [5]. Patients should 
be treated in a specialist centre or in a shared care 
setting as if they have a positive diagnosis of PCD. 
Other diseases causing chronic upper and lower 
respiratory disease should be ruled out, if this has 
not been done before PCD testing. This includes, 
for instance, sweat tests for CF and investigations to 
rule out immunodeficiency. As new diagnostic tests 
become available, further investigations should be 
offered [5].
Inconclusive
Patients with an inconclusive diagnosis should 
have further management and investigations 
determined by a PCD reference centre or a specialist 
with expertise in PCD. The Task Force recommends 
reassessing the patient periodically, and considering 
alternative diagnoses associated with chronic wet 
cough and chronic ENT symptoms. Similarly, 
repeat PCD testing should be reconsidered at 
regular intervals, as the patients grow up, and new 
diagnostic tests become available [5].
Highly unlikely
Where the diagnosis of PCD is highly unlikely, we 
recommend telling patients that further testing for 
PCD is not warranted [5]. Their GP and pulmonary/
ENT physicians will need to decide whether further 
investigations for other causes of their symptoms 
is needed.
Conclusion and future 
perspectives
The ERS PCD Task Force has recently delivered the 
first evidence-based guidelines for the diagnosis 
of PCD. Whilst the guidelines primarily aimed 
to standardise approaches by PCD experts, it is 
vitally important that primary and secondary care 
professionals understand the context of the decisions 
surrounding key recommendations; it is these 
physicians who need to identify patients to refer for 
diagnostic testing and might share care with the 
specialist PCD service if the diagnosis is confirmed.
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The diagnosis of PCD is a rapidly evolving 
field and in the few months since the Task Force 
guidelines were published, a new PCD gene has 
been discovered [31, 32] and evidence for the role 
of IF in a diagnostic setting has been published 
[27]. As new evidence arises, the guidelines will 
need revisiting and some patients should undergo 
repeat testing. More research is needed to clarify 
which patients should be tested. As we further our 
understanding of this heterogeneous condition, we 
are likely to find new phenotypes that challenge 
diagnostic decisions made in the current and past. 
There is no consensus on the approaches to most 
diagnostic tests, including HSVA and TEM; therefore, 
international standards are needed for the conduct 
and reporting of investigations.
Future studies investigating clinical symptoms 
should have a longitudinal cohort design including 
consecutive referrals, instead of case–control 
designs; additionally, these studies should be 
conducted in the health setting for which we want 
information (primary, secondary or tertiary care). 
Although tools such as PICADAR are promising 
[17], their predictive abilities are still modest. It 
might be possible to improve the accuracy of such 
clinical prediction models by adding information on 
nNO and on a broader variety of or better specified 
symptoms, and by adapting the tools to specific 
age ranges (infant, pre-schoolers, school children 
and adults). This should help to define better which 
patients should be referred to a diagnostic centre for 
further testing. At present, with a large majority of 
PCD patients undiagnosed, our primary goal is to aim 
for a high sensitivity (i.e. miss few patients). However, 
as diagnostic testing for PCD is time consuming and 
costly, we must also aim for high PPVs.
Patients must be diagnosed early and treatments 
installed as soon as possible, even for patients in 
whom the diagnosis is only highly likely rather 
than confirmed. Although published evidence is 
still scarce, it is likely that this will be beneficial for 
later lung function, long-term disease course and 
life expectancy.
Since the evidence for the effect of different 
treatments on the course of PCD is very limited, it is 
important that we give each patient opportunities to 
participate in coordinated programmes of research. 
Over recent years, there has been a huge increase 
in the number of patients recruited to national and 
international registries [33], consortia research 
programmes and cohort studies [12], and results 
from these programmes are starting to provide the 
much needed evidence-base for managing this rare 
disease [18, 34, 35].
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